In oncology drug development, from target discovery to IND filing, every critical decision point relies on robust, comprehensive data. Alfa Cytology has established a fully integrated testing service platform spanning the entire biological continuum—from molecular and cellular levels to tissue and whole-animal systems—delivering end-to-end support that covers gene-level target validation through to in vivo efficacy and safety assessment. Our testing services provide full-spectrum technical support for all types of preclinical research, available as standalone deliverables or flexibly combined with pharmacology and safety study packages to meet your program needs at every stage of development.
Our Services
Leveraging decades of institutional expertise and extensive experience in oncology drug development, Alfa Cytology has established a fully integrated preclinical testing service platform. This platform unites eight core technology modules, delivering comprehensive analytical capabilities spanning gene editing, cellular phenotyping, histopathology, in vivo functional assessment, and biochemical profiling.
Designed to address the rigorous demands of oncology drug discovery and development, our platform consolidates molecular biology, immunoassays, cell biology, histopathology, in vivo physiology, in vivo bioimaging, behavioral phenotyping, and biochemical/body fluid analysis within a unified quality framework—ensuring that every data point is traceable, reproducible, and decision-grade. Whether you are conducting functional validation of a specific target or performing systematic efficacy and safety evaluation of drug candidates, our testing services can be flexibly configured to deliver the critical data necessary for informed decision-making at every stage of your drug development program.
Integrated Testing Services for Drug Discovery & Development
Delivers gene-level target validation and biomarker analysis through PCR, qPCR, sequencing, and gene editing technologies, providing mechanistic insights that anchor drug discovery decisions in solid genetic evidence.
Delivers high-sensitivity protein quantification and immunogenicity assessment via ELISA, MSD, and Luminex platforms, generating critical data on cytokine profiles, ADA/NAb responses, and pharmacodynamic biomarkers.
Enables in vitro efficacy screening and mechanistic studies through proliferation, apoptosis, migration, and flow cytometry assays, delivering functional evidence to prioritize lead candidates before advancing to in vivo models.
Provides tissue-level efficacy and target engagement visualization through H&E staining, IHC, IF, and TUNEL assays, translating in vivo findings into morphological evidence of drug activity and toxicity.
Enables real-time, non-invasive tracking of tumor burden, metastasis, and drug biodistribution using bioluminescence, fluorescence, Micro-CT, MRI, and ultrasound, delivering longitudinal data without sacrificing animals.
Monitors cardiovascular, neurological, and microcirculatory function via ECG, EEG/EMG, and laser speckle imaging, providing safety pharmacology data essential for IND-enabling studies.
Evaluates cognitive, emotional, and motor functions in CNS drug discovery using standardized paradigms including Morris water maze, open field, elevated plus maze, and forced swim test, delivering phenotypic data that bridges neuropharmacology and behavior.
Provides clinical chemistry and hematology profiling, including liver/kidney function, blood routine, and urinalysis, delivering baseline safety data that support general toxicology and IND submission
How Our Testing Services Support Your Preclinical Research
| R&D Stage |
Corresponding Testing Support |
| Target Discovery & Validation |
- Molecular Biology Assay (gene-level target validation)
- Cell-Based Assay(functional validation)
|
| In Vitro Efficacy Screening |
- Cell-Based Assay (proliferation, apoptosis, migration)
- Immunoassays (cytokines/biomarkers)
|
| In Vivo Efficacy Evaluation |
- In Vivo Bioimaging (tumor burden/metastasis tracking)
- Histopathology (morphological confirmation)
- Behavioral Tests (for CNS agents)
|
| DMPK/ADME |
- Biochemical & Body Fluid Analysis (drug concentration)
- Immunoassays (ELISA-based PK detection)
|
| Safety Assessment |
- In Vivo Physiological Assays (ECG/EEG safety pharmacology)
- Biochemical & Body Fluid Analysis (liver/kidney function)
- Histopathology (toxicological histology)
- Immunoassays (immunogenicity/immunotoxicity)
|
Why Alfa Cytology?
Alfa Cytology's integrated testing platform is purpose-built to address the specific challenges of oncology drug development, where data quality and continuity directly determine the speed and success of program advancement.
- Full Biological Continuum Coverage: Our eight modules span gene→protein→cell→tissue→whole-animal analysis, delivering a seamless evidence chain that eliminates data inconsistency and cross-vendor communication overhead—reducing coordination costs by 30% or more.
- Oncology-Focused Expertise: Our scientific team comprises senior tumor biologists, pathologists, and pharmacologists who deeply understand the critical decision nodes in oncology drug development, providing translational insights that go beyond raw data.
- GLP-Compliant & Regulatory-Ready: All core platforms operate under GLP-compliant quality systems, delivering traceable, auditable data that directly support IND submissions for both US FDA and China NMPA.
- Flexible Service Models: Choose from individual module outsourcing to fully integrated program packages, custom-combined to match your project stage, timeline, and budget constraints.
- Data Continuity & Integrity: Unlike fragmented testing strategies that require multiple vendors, our unified platform ensures every dataset is generated, analyzed, and reported under consistent standards—giving you confidence in every decision.
Workflow of Our Service
Our integrated testing services follow a streamlined, transparent workflow designed to minimize turnaround time while maintaining the highest data quality standards.
Alfa Cytology offers flexible testing service packages customized to your program needs—whether you require a single assay for a specific endpoint or a fully integrated testing suite supporting your entire preclinical development timeline. If you are interested in exploring how our integrated testing services can accelerate your oncology drug development program, please feel free to contact us. Our scientific team is ready to provide one-on-one consultation and custom solution design.
For research use only.
Related Services
